SEARCH

SEARCH BY CITATION

References

  • Alegre, A., Diaz-Mediavilla, J., San-Miguel, J., Martinez, R., Garcia Larana, J., Sureda, A., Lahuerta, J.J., Morales, D., Blade, J., Caballero, D., De la Rubia, J., Escudero, A., Diez-Martin, J.L., Hernandez-Navarro, F., Rifon, J., Odriozola, J., Brunet, S., De la Serna, J., Besalduch, J., Vidal, M.J., Solano, C., Leon, A., Sanchez, J.J., Martinez-Chamorro, C. & Fernandez-Ranada, J.M. (1998) Autologous peripheral blood stem cell transplantation for multiple myeloma: a report of 259 cases from the Spanish Registry for Transplant in Multiple Myeloma and PETHEMA. Bone Marrow Transplant, 21, 133140.
  • Alexanian, R., Weber, D., Giralt, S., Dimopoulos, M., Delasalle, K., Smith, T. & Champlin, R. (2001) Impact of complete remission with intensive therapy in patients with responsive multiple myeloma. Bone Marrow Transplant, 27, 10371043.
  • Anderson, KC. (2003) The role of immunomodulatory drugs in multiple myeloma. Seminars in Hematology, 40, 2332.
  • Attal, M., Harousseau, J.L., Stoppa, A.M., Sotto, J.J., Fuzibet, J.G., Rossi, J.F., Casassus, P., Maisonneuve, H., Facon, T., Ifrah, N., Payen, C. & Bataille, R. (1996) A prospective randomised trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. New England Journal of Medicine, 335, 9197.
  • Bensinger, W.I., Rowley, S.D., Demirer, T., Lilleby, K., Schiffman, K., Clift, R.A., Appelbaum, F.R., Fefer, A., Barnett, T., Storb, R., Chauncey, T., Maziarz, R.T., Klarnet, J., McSweeney, P., Holmberg, L., Maloney, D.G., Weaver, C.H. & Buckner, C.D. (1996) High dose therapy followed by autologous hematopoietic stem cell infusion for patients with multiple myeloma. Journal of Clinical Oncology, 14, 14471456.
  • Bjorkstrand, B., Ljungman, P., Bird, J.M., Samson, D., Brandt, L., Alegre, A., Auzanneau, G., Blade, J., Brunet, S. & Carlson, K. (1995) Autologous stem cell transplantation in multiple myeloma: results of the European Group for Bone Marrow Transplantation. Stem Cells, 13, 140146.
  • Blade, J., San Miguel, J.F., Fontanillas, M., Alcala, A., Maldonado, J., Garcia-Conde, J., Conde, E., Conzalez-Brito, G., Moro, M.J., Escudero, M.L., Trujillo, J., Pascual, A., Rozman, C., Estape, J. & Montserrat, E. (1996) Survival of multiple myeloma patients who are potential candidates for early high dose therapy intensification/autotransplantation and who are conventionally treated. Journal of Clinical Oncology, 7, 21672173.
  • Blade, J., Esteve, J., Rives, S., Martinez, C., Rovira, M., Urbano-Ispizua, A., Marin, P., Carreras, E. & Montserrat, E. (2000) High dose therapy autotransplantation/intensification vs continued standard chemotherapy in multiple myeloma in first remission. Results of a non-randomised study from a single institution. Bone Marrow Transplant, 26, 845849.
  • Blade, J., Sureda, A., Ribera, J.M., Diaz-Mediavilla, J., Palomera, L., Fernandez-Calvo, J., Marti, J.M., Giraldo, P., Carbonell, F., Callis, M., Trujillo, J., Gardella, S., Moro, M.J., Barez, A., Soler, J.A., Font, L., Fontanillas, M. & Miguel, J.F. (2001) High dose therapy autotransplantation/intensification vs continued conventional chemotherapy in multiple myeloma in patients responding to initial treatment chemotherapy. Results of a prospective randomised trial from the Spanish Cooperative Group PETHEMA. Blood, 98, 815a (abstract 3386).
  • Child, J.A., Morgan, G.J., Davies, F.E., Owen, R.G., Bell, S.E., Hawkins, K., Brown, J., Drayson, M.T., Selby, P.J. & Medical Research Council Adult Leukaemia Working Party (2003) High-dose chemotherapy with haemopoietic stem-cell rescue for multiple myeloma. New England Journal of Medicine, 348, 18751883.
  • Davies, F.E., Forsyth, P.D., Rawstron, A.C., Owen, R.G., Pratt, G., Evans, P.A., Richards, S.J., Drayson, M., Smith, G.M., Selby, P.J., Child, J.A. & Morgan, G.J. (2001) The impact of attaining a minimal disease state after high dose melphalan and autologous transplantation for multiple myeloma. British Journal of Haematology, 112, 814819.
  • Desikan, R., Barlogie, B., Sawyer, J., Ayers, D., Tricot, G., Badros, A., Zangari, M., Munshi, N.C., Anaissie, E., Spoon, D., Siegel, D., Jagannath, S., Vesole, D., Epstein, J., Shaughnessy, J., Fassas, A., Lim, S., Robertson, P. & Crowley, J. (2000) Results of high-dose therapy for 1000 patients with multiple myeloma: durable complete remissions and superior survival in the absence of chromosome 13 abnormalities. Blood, 95, 40084010.
  • Durie, B.G. & Salmon, S.E. (1975) A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment and survival. Cancer, 36, 842854.
  • Facon, T., Avet-Loiseau, H., Guillerm, G., Moreau, P., Genevieve, F., Zandecki, M., Lai, J.L., Leleu, X., Jouet, J.P., Bauters, F., Harousseau, J.L., Bataille, R. & Mary, J.Y. (2001) Chromosome 13 abnormalities identified by FISH analysis and serum B2 microglobulin produce a powerful myeloma staging system for patients receiving high dose therapy. Blood, 97, 15661571.
  • Fermand, J.P., Ravaud, P., Chevret, S., Leblond, V., Divine, M., Dreyfus, F., Belanger, C., Troussard, X., Mariette, X. & Brouet, J.C. (1995) High dose therapy and autologous blood stem cell transplantation in multiple myeloma: preliminary results of a randomised trial involving 167 patients. Stem Cells, 13(Suppl. 2), 156159.
  • Gore, M.E., Selby, P.J., Viner, C., Clark, P.I., Meldrum, M., Millar, B., Bell, J., Maitland, J.A., Milan, S. & Judson, I.R. (1989) Intensive treatment of multiple myeloma and criteria for complete remission. Lancet, 2, 879882.
  • Greipp, P.R., San Miguel, J.F., Durie, B.G., Avet Loiseau, H., Fonseca, R., Jacobson, J.L., Rasmussen, E. & Crowley, J.J. (2003) A new international staging system for multiple myeloma from the International Myeloma Working Group. Blood, 102, Abstract 664.
  • Harousseau, J.L. & Attal, M. (2002) The role of stem cell transplantation in multiple myeloma. Blood Reviews, 16, 245253.
  • Harousseau, J.L., Attal, M., Divine, M. Marit, G., Leblond, V., Stoppa, A.M., Bourhis, J.H., Caillot, D., Boasson, M. & Abgrall, J.F. (1995) Autologous stem cell transplantation after first remission induction treatment in multiple myeloma: a report of the French Registry on autologous transplantation in multiple myeloma. Blood, 85, 30773085.
  • Kaufmann, H., Kromer, E., Nosslinger, T., Weltermann, A., Ackermann, J., Reisner, R., Bernhart, M. & Drach, J. (2003) Both chromosome 13 abnormalities by metaphase cytogenetics and deletion of 13q by interphase fluorescent in situ hybridisation only are prognostically relevant in multiple myeloma. European Journal of Haematology, 71, 179183.
  • Lahuerta, J.J., Martinez-Lopez, J., Serna, J.D., Blade, J., Grande, C., Alegre, A., Vazques, L., Garcia-Larana, J., Sureda, A., Rubia, J.D., Conde, E., Martinez, R., Perez-Equiza, K., Moraleda, J.M., Leon, A., Besalduch, J., Cabrera, R., Miguel, J.D., Morales, A., Garcia-Ruiz, J.C., Diaz-Mediavilla, J. & San-Miguel, J. (2000) Remission status defined by immunofixation vs electrophoresis after autologous transplantation has a major impact on the outcome of multiple myeloma. British Journal of Haematology, 109, 438446.
  • Maclennan, I.C., Chapman, C., Dunn, J. & Kelly, K. (1992) Combined chemotherapy with ABCM versus melphalan for treatment of myelomatosis. The Medical Research Council Working Party for Leukaemia in Adults. Lancet, 25, 200205.
  • Powles, R., Raje, N., Milan, S., Millar, B., Shepherd, V., Mehta, J., Singhal, S., Kulkarni, S., Viner, C., Gore, M., Cunningham, D. & Treleaven, J. (1997) Outcome assessment of a population-based group of 195 unselected myeloma patients under 70 years of age offered intensive treatment. Bone Marrow Transplant, 20, 435443.
  • Raje, N., Powles, R., Kulkarni, S., Milan, S., Middleton, G., Singhal, S., Mehta, J., Millar, B., Viner, C., Raymond, J., Treleaven, J., Cunningham, S. & Gore, M. (1997) A comparison of vincristine and doxorubicin infusional chemotherapy with methyprednisolone (VAMP) with the addition of weekly cyclophosphamide (CVAMP) as induction treatment followed by autografting in previously untreated myeloma. British Journal of Haematology, 97, 153160.
  • Rajkumar, S.V., Fonseca, R., Dispenzieri, A., Lacy, M.O., Witzig, T.E., Lust, J.A., Larson, D., Therneau, T.M., Kyle, R.A., Litzow, M.R., Greipp, P.R. & Gertz, M.A. (2000) Effect of complete response on outcome following autologous stem cell transplantation for myeloma. Bone Marrow Transplant, 26, 979983.
  • Richardson, P.G., Schlossman, R.L., Weller, E., Hideshima, T., Mitsiades, C., Davies, F., EBlanc, R., Catley, L.P., Doss, D., Kelly, K., McKenney, M., Mechlowicz, J., Freeman, A., Deocampo, R., Rich, R., Ryoo, J.J., Chauhan, D., Balinski, K., Zeldis, J. & Anderson, K.C. (2002) Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood, 100, 30633067.
  • Richardson, P.G., Barlogie, B., Berenson, J., Singhal, S., Jagannath, S., Irwin, D., Rajkumar, S.V., Srkalovic, G., Alsina, M., Alexanian, R., Siegel, D., Orlowski, R.Z., Kuter, D., Limentani, S.A., Lee, S., Hideshima, T., Esseltine, D.L., Kauffman, M., Adams, J., Schenkein, D.P. & Anderson, K.C. (2003) A phase 2 study of bortezomib in relapsed, refractory myeloma. New England Journal of Medicine, 348, 26092617.
  • Schey, S.A., Fields, P., Bartlett, J.B., Clarke, I.A., Ashan, G., Knight, R.D., Streetly, M. & Dalgleish, A.G. (2004) Phase I study of an immunomodulatory thalidomide analog, CC-4047, in relapsed or refractory multiple myeloma. Journal of Clinical Oncology, 22, 32693276.
  • Shaughnessy, J., Jacobson, J., Sawyer, J., McCoy, J., Fassas, A., Zhan, F., Bumm, K., Epstein, J., Anaissie, E., Jagannath, S., Vesole, D., Siegel, D., Desikan, R., Munshi, N., Badros, A., Tian, E., Zangari, M., Tricot, G., Crowley, J. & Barlogie, B. (2003) Continuous absence of metaphase-defined cytogenetic abnormalities, especially of chromosome 13 and hypodiploidy, ensures long-term survival in multiple myeloma treated with total therapy I: interpretation in the context of global gene expression. Blood, 101, 38493856.
  • Singhal, S., Mehta, J., Desikan, R., Ayers, D., Roberson, P., Eddlemon, P., Munshi, N., Anaissie, E., Wilson, C., Dhodapkar, M., Zeddis, J. & Barlogie, B. (1999) Antitumor activity of thalidomide in refractory multiple myeloma. New England Journal of Medicine, 341, 15651571.
  • Sirohi, B., Powles, R., Kulkarni, S., Rudin, C., Saso, R., Rigg, A., Horton, C., Singhal, S., Mehta, J. & Treleaven, J. (2001) Glomerular filtration rate prior to high-dose melphalan 200 mg/m2 as a surrogate marker of outcome in patients with multiple myeloma. British Journal of Cancer, 85, 325332.
  • Tricot, G., Sawyer, J.R., Jagannath, S. Desikan, K.R., Siegel, D., Naucke, S., Mattox, S., Bracy, D., Munshi, N. & Barlogie, B. (1997) Unique role of cytogenetics in the prognosis of patients with myeloma receiving high dose therapy and autotransplants. Journal of Clinical Oncology, 7, 26592666.
  • Vesole, D.H., Crowley, J.J., Catchatourian, R., Stiff, P.J., Johnson, D.B., Cromer, J., Salmon, S.E. & Barlogie, B. (1999) High-dose melphalan with autotransplantation for refractory multiple myeloma: results of a Southwest Oncology Group phase II trial. Journal of Clinical Oncology, 17, 21732179.
  • Zojer, N., Konigsberg, R., Ackermann, J., Fritz, E., Dallinger, S., Kromer, E., Kaufmann, H., Riedl, L., Gisslinger, H., Schreiber, S., Heinz, R., Ludwig, H., Huber, H. & Drach, J. (2000) Deletion of 13q14 remains an independent adverse prognostic variable in multiple myeloma despite its frequent detection by interphase fluorescent in situ hybridisation. Blood, 95, 19251930.